The geoepidemiology of Sjogren's syndrome

被引:235
作者
Mavragani, Clio P. [1 ]
Moutsopoulos, Haralampos M. [2 ]
机构
[1] Univ Athens, Sch Med, Dept Expt Physiol, GR-11527 Athens, Greece
[2] Univ Athens, Sch Med, Dept Pathophysiol, GR-11527 Athens, Greece
关键词
Sjogren's syndrome; Pathogenesis; Clinical features; Therapy; Differential diagnosis; Lymphoma; CLASSIFICATION CRITERIA; EPITHELIAL-CELLS; DEFICIENT MICE; PREVALENCE; INTERFERON; IRF5; INTERLEUKIN-17; POLYMORPHISM; ACTIVATION; MIZORIBINE;
D O I
10.1016/j.autrev.2009.11.004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Sjogren's syndrome (SS) is a slowly progressing autoimmune disease, affecting predominantly middle-aged women, with a female to male ratio reaching 9:1. It is characterized by lymphocytic infiltration of the exocrine glands, mainly the lacrimal and salivary glands, resulting in reduced secretory functions and oral and ocular dryness. The syndrome can present alone as primary SS (pSS) or in the context of underlying connective tissue disease as secondary SS (sSS). While the pathogenesis of the disease remains elusive, environmental, genetic and hormonal contributors seem to be involved. Over the last years, compelling evidence has suggested a pivotal role of the epithelium in orchestrating the immune response in the histopathological lesion of Sjogren's syndrome and the term "autoimmune epithelitis" has been proposed as an etiological term. Although the clinical manifestations of pSS patients are mainly those of an autoimmune exocrinopathy, almost half of patients develop extraglandular disease, which may be manifested either by epithelial lymphocytic invasion of lung, liver, or kidney (resulting in interstitial nephritis) or by skin vasculitis, peripheral neuropathy, glomerulonephritis, and low C4 levels. The latter reflect immune-complex mediated disease and confer increased risk for lymphoma development. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:A305 / A310
页数:6
相关论文
共 40 条
[1]   Activation of the type I interferon system in primary Sjogren's syndrome -: A possible etiopathogenic mechanism [J].
Båve, U ;
Nordmark, G ;
Lövgren, T ;
Rönnelid, J ;
Cajander, S ;
Eloranta, ML ;
Alm, GV ;
Rönnblom, L .
ARTHRITIS AND RHEUMATISM, 2005, 52 (04) :1185-1195
[2]   Foxp3+ T-Regulatory Cells in Sjogren's Syndrome Correlation with the Grade of the Autoimmune Lesion and Certain Adverse Prognostic Factors [J].
Christodoulou, Maria I. ;
Kapsogeorgou, Efstathia K. ;
Moutsopoulos, Niki M. ;
Moutsopoulos, Haralampos M. .
AMERICAN JOURNAL OF PATHOLOGY, 2008, 173 (05) :1389-1396
[3]   Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway [J].
Espinosa, Alexander ;
Dardalhon, Valerie ;
Brauner, Susanna ;
Ambrosi, Aurelie ;
Higgs, Rowan ;
Quintana, Fransisco J. ;
Sjostrand, Maria ;
Eloranta, Maija-Leena ;
Gabhann, Joan Ni ;
Winqvist, Ola ;
Sundelin, Birgitta ;
Jefferies, Caroline A. ;
Rozell, Bjorn ;
Kuchroo, Vijay K. ;
Wahren-Herlenius, Marie .
JOURNAL OF EXPERIMENTAL MEDICINE, 2009, 206 (08) :1661-1671
[4]   Efficacy of tacrolimus in Sjogren's syndrome-associated CNS disease with aquaporin-4 autoantibodies [J].
Fukuda, Taku ;
Shiraishi, Hirokazu ;
Nakamura, Tatsufumi ;
Tanaka, Keiko ;
Nakamura, Hideki ;
Tsujino, Akira ;
Nishiura, Yoshihiro ;
Yoshimura, Toshiro ;
Motomura, Masakatsu ;
Eguchi, Katsumi .
JOURNAL OF NEUROLOGY, 2009, 256 (10) :1762-1764
[5]   Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases [J].
Gabriel, Sherine E. ;
Michaud, Kaleb .
ARTHRITIS RESEARCH & THERAPY, 2009, 11 (03)
[6]   Estimation of the prevalence of primary Sjogren's syndrome in two age-different community-based populations using two sets of classification criteria:: the Hordaland Health Study [J].
Haugen, A. J. ;
Peen, E. ;
Hulten, B. ;
Johannessen, A. C. ;
Brun, J. G. ;
Halse, A. K. ;
Haga, H-J .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 (01) :30-34
[7]   Prevalence of Sjogren syndrome among Nagasaki atomic bomb survivors [J].
Hida, A. ;
Akahoshi, M. ;
Takagi, Y. ;
Ashizawa, K. ;
Imaizumi, M. ;
Soda, M. ;
Maeda, R. ;
Nakashima, E. ;
Ida, H. ;
Kawakami, A. ;
Nakamura, T. ;
Eguchi, K. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (05) :689-695
[8]   B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome [J].
Ittah, Marc ;
Miceli-Richard, Corinne ;
Gottenberg, Jacques-Eric ;
Lavie, Frederic ;
Lazure, Thierry ;
Ba, Nathalie ;
Sellam, Jeremie ;
Lepajolec, Christine ;
Mariette, Xavier .
ARTHRITIS RESEARCH & THERAPY, 2006, 8 (02)
[9]   Stress, coping strategies and social support in patients with primary Sjogren's syndrome prior to disease onset: a retrospective case-control study [J].
Karaiskos, D. ;
Mavragani, C. P. ;
Makaroni, S. ;
Zinzaras, E. ;
Voulgarelis, M. ;
Rabavilas, A. ;
Moutsopoulos, H. M. .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (01) :40-46
[10]   Clinical manifestations and early diagnosis of Sjogren syndrome [J].
Kassan, SS ;
Moutsopoulos, HM .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (12) :1275-1284